Novoste Parrying Drug-Coated Stents With Planned Indications For Beta-Cath
Novoste will rely on supplemental indications unaddressed by drug-coated stent developers to increase adoption of its Beta-Cath vascular brachytherapy system.
Novoste will rely on supplemental indications unaddressed by drug-coated stent developers to increase adoption of its Beta-Cath vascular brachytherapy system.